Research programme: autoimmune disease therapeutics - Atreca/Janssen Biotech
Latest Information Update: 28 Jan 2019
At a glance
- Originator Atreca
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
- 02 Dec 2014 Early research in Autoimmune disorders in USA (Parenteral)